Nuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy.
Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland.
Hormones (Athens). 2020 Sep;19(3):341-349. doi: 10.1007/s42000-020-00178-x. Epub 2020 Feb 10.
The incidence and clinical significance of thyroiditis detected by molecular imaging methods is a clinical challenge that is not widely investigated in the literature. The aim of this systematic review was to analyze published data about the detection of thyroiditis on PET or PET/CT using different tracers.
A comprehensive computer literature search of the Scopus, PubMed/MEDLINE, Embase, and Cochrane library databases was conducted up to November 2019 to find relevant papers on the detection of thyroiditis by PET/CT, the metabolic appearance, and the clinical significance.
Twenty-six articles were selected and retrieved in full-text version. From the analyses of these studies, the following main findings have been found. Diffuse thyroid uptake of PET tracers is a relatively frequent event, ranging from 0.4 to 46.2%, and it is commonly related to benign disease. Thyroiditis is the most frequent reason for diffuse increased thyroid F-FDG uptake. Cases of malignant disease with a pattern of diffuse F-FDG thyroid uptake are less frequent. Preliminary studies show a possible role of thyroiditis detected by F-FDG PET/CT in evaluating treatment response and as a prognostic marker in oncological patients treated with immunotherapy. However, further studies are needed.
Diffuse F-FDG thyroid uptake is a relatively rare event commonly due to benign diseases, among which thyroiditis is the most common. The rate of neoplastic disease with diffuse F-FDG thyroid uptake is very low. Diffuse F-FDG thyroid uptake requires further investigation and clinical evaluation for the correct diagnosis. Currently, cases of diffuse thyroid uptake with non-F-FDG radiotracer are only anecdotal.
分子影像学方法检测到的甲状腺炎的发生率和临床意义是一个尚未广泛研究的临床挑战。本系统评价的目的是分析使用不同示踪剂的 PET 或 PET/CT 检测甲状腺炎的已发表数据。
对 Scopus、PubMed/MEDLINE、Embase 和 Cochrane 图书馆数据库进行了全面的计算机文献检索，以查找有关使用 PET/CT、代谢表现和临床意义检测甲状腺炎的相关文献。
选择并全文检索了 26 篇文章。通过对这些研究的分析，发现了以下主要结果。PET 示踪剂的弥漫性甲状腺摄取是一种相对常见的现象，范围从 0.4 到 46.2%，通常与良性疾病有关。甲状腺炎是弥漫性甲状腺 F-FDG 摄取增加的最常见原因。弥漫性 F-FDG 摄取模式的恶性疾病病例较少见。初步研究表明，FDG PET/CT 检测到的甲状腺炎在评估治疗反应和作为接受免疫治疗的肿瘤患者的预后标志物方面可能具有一定作用。但是，还需要进一步的研究。
弥漫性 F-FDG 甲状腺摄取是一种相对罕见的现象，通常是良性疾病所致，其中甲状腺炎最为常见。弥漫性 F-FDG 摄取的肿瘤性疾病发生率非常低。弥漫性 F-FDG 甲状腺摄取需要进一步的调查和临床评估以做出正确的诊断。目前，非 F-FDG 放射性示踪剂的弥漫性甲状腺摄取仅为偶发案例。
